Evidence map›Paper›PMID 26540400›Full record

ArticleCritical care medicine2016

A Dysregulated Balance of Proinflammatory and Anti-Inflammatory Host Cytokine Response Early During Therapy Predicts Persistence and Mortality in Staphylococcus aureus Bacteremia.

Emi Minejima, Joyce Bensman, Rosemary C She, Wendy J Mack, Martin Tuan Tran, Pamela Ny, Mimi Lou, Jason Yamaki, Paul Nieberg, Joyce Ho and 1 more

Open access · greenAbstract read
In one paragraph

Article in Critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Complex Intracellular Lifecycle ofInternational journal of molecular sciences · 2024
    Review
  7. Article
  8. Determining the Prognostic Value of Complete Blood Count Subgroup Parameters inJournal of patient-centered research and reviews · 2024
    Article
  9. Article
  10. Global Differences in the Management of Staphylococcus aureus Bacteremia: No International Standard of Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  11. Article
  12. Persistent Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Persistent Methicilin-Resistant Staphylococcus aureus Bacteremia: Resetting the Clock for Optimal Management.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Emi Minejima1Department of Pharmacy, University of Southern California, Los Angeles, CA. 2Department of Pathology, Keck School of Medicine, Los Angeles, CA. 3Department of Preventative Medicine, Keck School of Medicine, Los Angeles, CA. 4Department of Pharmacy, Huntington Hospital, Pasadena, CA. 5Department of Medicine, Huntington Hospital, Pasadena, CA.
Joyce Bensman
Rosemary C She
Wendy J Mack
Martin Tuan Tran
Pamela Ny
Mimi Lou
Jason Yamaki
Paul Nieberg
Joyce Ho
Annie Wong-Beringer
National Center for Advancing Translational Sciences · USUniversity of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
NCATS NIH HHS UL1 TR000130NCATS NIH HHS UL1TR000130NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectivesThe contribution of individual immune response to Staphylococcus aureus bacteremia on outcome has not been well studied. The objective was to relate the host cytokine response to outcome of Staphylococcus aureus bacteremia.

designProspective observational study.

settingThree U.S. university-affiliated medical centers. PATIENTS: Adult patients infected with Staphylococcus aureus bacteremia hospitalized between July 2012 and August 2014.

interventionsBlood specimens were obtained at Staphylococcus aureus bacteremia onset and 72 hours after therapy initiation. Levels of tissue necrosis factor, interleukin-6, interleukin-8, interleukin-17A, and interleukin-10 were measured by enzyme-linked immunosorbent assay at each time point and compared between those with persistent bacteremia (≥ 4 d) and resolving bacteremia. Primary outcome was persistent bacteremia after 4 days of effective therapy. Secondary outcomes were 30-day mortality and 30-day recurrence. MEASUREMENTS AND MAIN

resultsA total of 196 patients were included (mean age, 59 yr); of them, 33% had methicillin-resistant Staphylococcus aureus bacteremia. Forty-seven percent of the methicillin-resistant Staphylococcus aureus strains were staphylococcal cassette chromosome mec IV. Persistent bacteremia occurred in 24% of patients (47/196); they were more likely to die than resolving bacteremia group (28% vs 5%; p < 0.001). Compared with resolving bacteremia group, persistent bacteremia patients had higher initial median levels of tissue necrosis factor (44.73 vs 21.68 pg/mL; p < 0.001), interleukin-8 (124.76 vs 47.48 pg/mL; p = 0.028), and interleukin-10 (104.31 vs 29.72 pg/mL; p < 0.001). Despite 72 hours of treatment, levels remained higher for the persistent bacteremia group than for the resolving bacteremia group (tissue necrosis factor: 26.95 vs 18.38 pg/mL, p = 0.02; interleukin-8: 70.75 vs 27.86 pg/mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001). Interleukin-17A levels were similar between groups at both time points. After controlling for confounding variables by multivariate analysis, interleukin-10/tissue necrosis factor ratio at 72 hours most significantly predicted persistence (odds ratio, 2.98; 95% CI, 1.39-6.39; p = 0.005) and mortality (odds ratio, 9.87; 95% CI, 2.64-36.91; p < 0.001) at values more than 1.00 and more than 2.56, respectively.

conclusionsSustained elevation of interleukin-10/tissue necrosis factor ratio at 72 hours suggests a dysregulated immune response and may be used to guide management to improve outcomes.

Indexed as

AdultAgedAnti-Bacterial AgentsBacteremiaFemaleHumansInterleukinsMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedProspective StudiesStaphylococcal InfectionsStaphylococcus aureusTreatment OutcomeTumor Necrosis Factor-alphaUnited StatesAnti-Bacterial AgentsInterleukinsTumor Necrosis Factor-alpha

Identifiers

PMID26540400
PMCPMC6504958
OpenAlexW2318701185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.